spec sheet6 rows
T-588 came out of Toyama Chemical in Japan as a multi-target cognitive enhancer built for the vascular-dementia and post-stroke cognitive-impairment niche that Japanese pharma researched heavily in the 1990s, a market segment Western companies mostly ignored. Rather than hitting one clean receptor, it increased acetylcholine and noradrenaline release in the cortex and hippocampus, blocked an outward potassium current in CA1 neurons, and protected cerebellar granule cells from glutamate excitotoxicity, a genuinely broad-spectrum profile aimed at both boosting transmission and shielding neurons from ischemic damage. It compensated for scopolamine-induced learning impairment and improved working memory after simulated cerebral ischemia in rodents, but like most Japanese vascular-cognition compounds of its era, it never crossed into Western regulatory pipelines and faded from view once academic interest moved to other neuroprotective targets.
- improved working memory deficits following simulated cerebral ischemia in rats
- partially compensated for scopolamine-induced motor associative learning impairment in mice
- protected cerebellar granule cells from glutamate neurotoxicity in vitro
- protected against experimental cerebral anoxia damage in animal models
- reversed learning/memory deficits in several rodent impairment paradigms
- sigma-receptor mechanism distinct from cholinesterase-inhibitor nootropics
- part of a documented 1990s Japanese cerebroprotective drug research effort
- T-588 blocks an outward potassium current in hippocampal CA1 neurons, a mechanism that overlaps with how the KCNQ-blocking cognitive enhancer linopirdine works, even though the two compounds are chemically unrelated.
- T-588's full chemical name is a mouthful even by nootropic standards: R(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride.
- It belongs to the same 1990s Japanese cerebroprotective research wave that also produced compounds like T-817MA's later successors.
Mechanism
Sigma receptor with reported cerebroprotective activity against experimental cerebral anoxia and ischemia; proposed to support cholinergic and monoaminergic function under conditions of cerebral insult, improving performance in rodent learning and memory-impairment paradigms.
Safetyrisks and cautions, not medical advice
No human trial of T-588 has been published, so its safety in people is unknown rather than reassuring. The record is entirely rodent and cell work from the 1990s and early 2000s: cerebral anoxia models, scopolamine-impaired mice, cultured spinal motor neurons. Nothing in that literature reports a toxicity signal, but preclinical studies are not designed to find one, and a compound that raises acetylcholine and noradrenaline release while blocking a potassium current has several plausible ways to cause trouble that were never tested in a person.
History
Developed by Toyama Chemical (Japan); characterized through the 1990s in rodent cerebral-anoxia and memory-impairment models, notably by Ono and colleagues in the Japanese Journal of Pharmacology (1993); no record of it advancing beyond preclinical and early pharmacology research to marketed status.
Resources
This entry is here for reference.
Research
- 1993first citedProtective effect of R(-)-1-(benzo[b]thiophen-5-yl)- 2-[2-(N,N-diethylamino)ethoxy]ethanol hydr…
- 2007most recentThe cognitive enhancer T-588 partially compensates the motor associative learning impairments i…
- 1.Effects of T-588, a newly synthesized cognitive enhancer, on hippocampal CA1 neurons in rat brain tissue slices
- 2.The cognitive enhancer T-588 partially compensates the motor associative learning impairments induced by scopolamine injection in mice
- 3.Protective effect of R(-)-1-(benzo[b]thiophen-5-yl)- 2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride (T-588), a novel cerebral activator, against experimental cerebral anoxia.
3 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is T-588 a racetam?
No, it is structurally unrelated to the pyrrolidinone racetams; it is a benzothiophene-based compound with a distinct multi-target mechanism combining neurotransmitter release enhancement, potassium-channel effects, and neuroprotection.
Why isn't T-588 better known outside Japan?
It was studied almost entirely within Japanese academic pharmacology aimed at vascular dementia, a research niche that Western Alzheimer's-focused pharma largely bypassed, so it never entered international clinical development.
Was T-588 ever tested in humans?
There is no published record of human trials; the available literature is limited to 1990s rodent pharmacology studies from Toyama Chemical researchers.
What does 'cerebral activator' mean in this context?
It was the era's marketing shorthand for compounds meant to protect and support brain function during ischemic or anoxic stress, a category that produced many Japanese and European research candidates in the 1990s, most of which never reached market.
Limitations of the evidence
- no human safety or tolerability data was ever published; it remained a preclinical research compound
- no human safety or efficacy data was ever published
- never advanced past preclinical/early pharmacology research
- mechanism characterized only in 1990s-era animal pharmacology
Notes and cautions
- unavailable commercially anywhere